Abstract: The process of reducing the count of a virus by contacting the virus with(1) the reaction product ofa) N-substituted propylenediamines corresponding to formula I:R.sup.1 --NH--CH.sub.2 --CH.sub.2 --CH.sub.2 --NH.sub.2 (I)In which R.sup.1 is a linear alkyl radical containing 12 to 14 carbon atoms, withb) compounds corresponding to formula II: ##STR1## in which R.sup.2 is an alkyl radical containing 1 to 4 carbon atoms or a hydrogen atom, the molar ratio of a) to b) is 1:1 to 1:2 and the reaction is carried out over a period of 0.5 to 10 hours at 60.degree. C. to 175.degree. C. with elimination of alcohol or water, and optionally,(2) wherein the reaction product is further reacted with ethylene oxide or propylene oxide, and optionally,(3) salt formation of the products obtained in (1) or (2) with inorganic or organic acids.

Abstract: The salts of S(+) 2-(3-benzoylphenyl)propionic acid and of R(-) 2-(3-benzoylphenyl)propionic acid with an organic base such as D-lysine, L-lysine, L-arginine, (R) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol and (S) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol, the process for their preparation and the corresponding pharmaceutical compositions containing said salts are described.

Abstract: A process for preparing polymeric amides is disclosed. The process comprises sequentially reacting a hydrocarbon polymer functionalized (e.g., via the Koch reaction) to contain acid, ester, thioacid and/or thioester groups with a heavy polyamine to form a partially derivatized product in which at least about 85% of the functional groups are converted to heavy (thio)amide groups, and then reacting the partially derivatized product with an excess of light amine to complete the derivatization by converting substantially all of the remaining functional groups to light (thio)amide groups. Products of the foregoing process are also disclosed, which products are useful as additives in fuels and in lubricants.

Abstract: N-chloroacetylglutamine is produced by reacting chloroacetyl chloride with an alkaline aqueous solution of glutamine the presence of a water-immiscible organic solvent, separating an aqueous layer by liquid-liquid separation, and crystallizing N-chloroacetyl-glutamine from the aqueous layer under acidic conditions. N-Chloroacetyl-glutamine useful as an intermediate for producing glycyl-L-glutamine which has higher stability than L-glutamine and is used as a component of an infusion solution can be obtained with high efficiency at low cost.

Abstract: The present specification discloses a ruminant feed additive composition which contains as an active ingredient a phosphoric acid-amino acid-polyvalent metal composite salt (final composite salt) which is insoluble in neutral or alkaline water and is soluble in acidic water and which can be obtained by treating a composite salt composed of a basic amino acid, magnesium and phosphoric acid with a salt of a divalent or trivalent (polyvalent) metal other than magnesium, or by treating the above-mentioned composite salt with the polyvalent metal salt and a condensed phosphoric acid component (alone) or the condensed phosphoric acid component and a phosphoric acid component (in combination), this composition taking the form of a powder or granules.

Abstract: The present disclosure details the preparation of hydroxamic-acid based bifunctional chelators and their use in conjugating metal ions to proteins and nucleic acids for tumor or tissue imaging or therapy purposes. Some preferred aspects of the disclosure involve the preparation of trisuccin, chemical name N-?tris(2-N- benzyloxyaminocarbonylethyl)! methylsuccinamic acid, which is a hydroxamic acid/succinate based structure that is particularly useful for binding radionuclides such as .sup.99m Tc, .sup.186 Re and .sup.67 Cu.

Abstract: 4,7,10,13,16,19-cis-Docosahexaenoic acid (DHA) salts with basic amino acids, in particular arginine and lysine, have favorable therapeutic and technological characteristics compared with the acid.

Abstract: The present invention relates to an amine compound represented by the following general formula (1): ##STR1## wherein R.sup.1 and R.sup.2 represent individually a linear or branched C.sub.1 -C.sub.24 alkyl or alkenyl group which may be substituted by a hydroxyl group, X.sup.1 represents a C.sub.1 -C.sub.6 alkylene or alkenylene group which may be substituted by a hydroxyl, sulfonic or carboxyl group, Y.sup.1 represents a carboxyl or sulfonic group, or a sulfuric acid residue, Y.sup.2 represents a hydroxyl group, a sulfuric acid residue or a group --OCO--X.sup.1 --COOH, Z represents a sulfoalkyl group or a group obtained by removing an amino group from an amino acid or a salt thereof, and n represents a number of 0 or 1, or a salt or quaternized product thereof, an intermediate useful for the preparation thereof, and detergent compositions containing such an amine compound.

Abstract: An arginine silicate-containing complex and its use in the prevention and treatment of atherosclerosis and as a dietary supplement. The arginine silicate complex is synthesized by combining arginine, potassium silicate and inositol. The complex is administered orally three times per day in an amount ranging from about 250 mg to about 2,500 mg as a preventative or therapeutic agent.

Abstract: Diethylenetriaminepentaacetic acid monoamide derivatives, their complexes and complex salts, containing an element of atomic numbers 21-29, 31, 32, 39, 42-44, 49 or 57-83, pharmaceutical agents containing these compounds, their use as contrast media and process for their production.

Abstract: The present invention is directed to a process for making (2S,5S)-5-fluoromethylornithine through the reaction of wet penicillin acylase with (2R,5R) and (2S,5S)-6-fluoromethyl-3-(phenylactyl)-amino-2-piperidone and the addition of an acid to the resulting product.

Abstract: Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen, alkyl, aralkyl, --COR.sup.a, --COR.sup.b, --CSR.sup.a, --CSR.sup.b, --SO.sub.2 R.sup.b, --CONHR.sup.b, --CSNHR.sup.b, --CONR.sup.b R.sup.b or --CSNR.sup.b R.sup.b ; R.sup.2 is hydrogen or alkyl; R.sup.3 is hydrogen, alkylidene, substituted alkyl, or R.sup.b ; R.sup.4 is optionally substituted alkyl, cycloalkyl, or aryl; R.sup.5 is R.sup.b O--, R.sup.b R.sup.b N--, R.sup.b HN--, aralkyloxycarbonyloxy or aralkyloxycarbonylamino, or R.sup.5 is --(CH.sub.2).sub.p --D--(CH.sub.2).sub.r --, where D is a single bond, carbonyl, oxygen, sulfur, --NH--, --(CH.sub.2 .dbd.CH.sub.2)-- or --NHCO--; and p and r are each 0 or an integer from 1 to 5; A is --(CH.sub.2).sub.m --B--(CH.sub.2).sub.n -- where B is a single bond, carbonyl, oxygen, sulfur, --NH--, --(CH.sub.2 .dbd.CH.sub.2)-- or --NHCO--; and m and n are each 0 or an integer from 1 to 5; R.sup.a is alkoxy, aralkyloxy, aryloxy or alkoxycarbonyl; R.sup.

Abstract: Combinatorial libraries comprising compounds of the formula ##STR1## where R.sub.1, R.sub.2, and R.sub.3 are each independently groups of the formula --C(O)R, whereR is an organic radical;x, y, and z are each independently 1, 2, 3, or 4;R.sub.4 is alkyl, alkenyl, aryl, aralkyl, acyl, amino, hydroxy, alkoxy, aryloxy, arylalkoxy, heterocyclyl, or H, or is a solid support; andR.sub.5 is alkyl, alkenyl, aryl, aralkyl, acyl, amino, hydroxy, alkoxy, aryloxy, arylalkoxy, heterocyclyl, or H are disclosed.

Abstract: Phosphoinositol-glycan-peptide with insulin-like actionPhosphoinositol-glycan-peptides obtainable by cleavage of adenosine 3',5'-cyclic monophosphate-binding protein, which contain glucosamine, galactose, mannose, inositol, phosphoric acid, ethanolamine and a peptide with the sequence Asx-Cys-Tyr, the preparation and use thereof for the treatment of diabetes mellitus and non-insulin-dependent diabetes are described.

Abstract: A compound of the formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.

Abstract: Compounds and methods are disclosed that are useful in inhibiting the TNF-.alpha. converting enzyme (TACE) responsible for cleavage of TNF-.alpha. precursor to provide biologically active TNF-.alpha.. The compounds employed in the invention are peptidyl derivatives having active groups capable of inhibiting TACE such as, hydroxamates, thiols, phosphoryls and carboxyls.

Abstract: Compounds in which peptides, amino acids, or derivatives of these compounds are conjugated to fatty acids, including ethanolamine and tromethamine. The fatty acids facilitate the therapeutic use of the compounds by enhancing immunogenic properties of the compounds, enhancing absorption of the peptide-fatty acid conjugates and providing slow release delivery of the compounds.

Abstract: In this method, one attaches one or more chelatant molecules to a mono- or polyamino intermediate compound I which is temporarily immobilized on a solid phase by a splittable bond. Thereafter, said bond is split to release the desired conjugate moiety, whereby a reactive site is generated at the splitting site. The conjugate can be coupled to a protein homing factor using said reactive site; the latter being single per chelatant molecule, undesirable cross-linking during conjugation is substantially avoided.

Abstract: Dendritic derivatives of 3,5-bis(aminomethyl)benzene and aminomethyl benzene core groups are disclosed. In each derivative, termed an "amplifier" because the dendritic structure on each molecule terminates with multiple termini to each of which an "active group" can be attached, the desired effect of the active group per mole is amplified compared to conventional compounds having only one active group per molecule. Amplifier molecules can include a targeting group permitting the molecules to preferentially attach to a particular anatomical or physiological situs. Active groups are any of various pharmacologically or therapeutically active moieties, including moieties useful for magnetic-resonance contrast enhancement. The dendritic structures comprise linkers and branch groups covalently bonded to each other in any of various structural combinations. The amplifiers can be prepared as a solution or mixture with a physiologically compatible carrier for administration to a warm-blooded animal subject.

Abstract: Disclosed are compounds, compositions and methods for inhibiting interleukinprotease activity. The compounds, .alpha.-substituted acetamides a ##STR1## wherein: R.sub.2 =H or alkyl;R.sup.3 =halo, O(CO).sub.0-1 aryl, OPOR.sup.4 R.sup.5 ; ##STR2## where R.sup.4 and R.sup.5 =aryl;R.sup.6 =H, aryl or aralkyl;R.sup.7 =independently selected from R.sup.6, CF.sub.3 and CF.sub.2 CF.sub.3 ;R.sup.1 =R.sup.6 -CO, heteroaryl-CO, heteroaralkyl-CO and amino acid.

Abstract: Fluorinated alkene compounds useful for and methods of controlling nematodes, insects, and acarids that prey on agricultural crops. Polar compounds, for example, 3,4,4-trifluoro-3-butene-1-amine or 3,4,4-trifluoro-3-butenoic acid, are particularly useful for systemic control of pests. Novel method and intermediates for the preparation of 3,4,4-trifluoro-3-butene-1-amine are also provided.

Abstract: Compounds wherein therapeutic peptides are covalently linked to phospholipids, glycerides or other membrane-targeting and membrane-anchoring species, and their pharmaceutically acceptable salts, together with processes for their preparation. The targeting technology is applicable to HIV protease inhibitors and a variety of other enzyme inhibitors.

Abstract: Disclosed is a process for producing alanylglutamine, which comprises reacting an N-(2-substituted)-propionylglutamine compound represented by the formula (I): ##STR1## where X represents halogen, alkylsulfonyloxy, or substituted or unsubstituted arylsulfonyloxy, with ammonia at a temperature of 60.degree. C. or below.in accordance with the present invention, highly purified alanylglutamine can be produced in a high yield, without racemization.

Abstract: The present invention relates to compounds that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, and for use in multi-drug resistant cancer therapy.

Abstract: A process for producing aminocarnitine is described, wherein methanesulfonylcarnitine is converted to a lactone which is reacted with an azide to give azidocarnitine. The catalytic hydrogenation of azidocarnitine gives aminocarnitine.

Abstract: A process is described for preparing aminoethylglycine from diaminoethane and glyoxylic acid by means of reductive amination.

Abstract: The present invention relates to a tripepride having the amino acid sequence Alanine-lsoleucine-Phenylalanine. This invention also relates to methods and compositions for inhibiting growth of dental plaque on tissues within an oral cavity of a human or other animal comprising topical administration, to tissues of such oral cavity, of a composition comprising a safe and effective amount of the tripepride.

Abstract: A method for synthesizing polypeptides from amino acids and/or peptides utilizing a novel reaction medium containing a hydrated silica entity containing silanol groups which function as an inorganic enzyme.

Abstract: Described herein are peptide derivatives of the formula R.sup.1 NH--CO--Q--C(O)--NR.sup.2 --CH[CH.sub.2 C(O)--Y]--C(O)--NH--CH[CR.sup.3 (R.sup.4)--COOH]--C(W)--NH--CHR.sup.5 --Z wherein R.sup.1 is an optionally substituted alkyl or optionally substituted phenylalkyl, R.sup.2 is hydrogen or alkyl, R.sup.3 and R.sup.4 each independently is hydrogen or alkyl, or R.sup.3 and R.sup.4 are joined to form a cycloalkyl. R.sup.5 is alkyl, cycloalkyl or (cycloalkyl)alkyl, Q is a divalent radical, for example, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH-- or 1,2-cyclohexanediyl, which serves as a two carbon spacer. W is oxo or thioxo, Y is, for example, an alkoxy or a monosubstituted or disubsdtuted ammo, and Z is a terminal unit, for example, hydrogen, COOH or CH.sub.2 OH. The derivatives are useful for treating herpes infections.

Abstract: The present invention relates to novel technetium-99m complexes and to methods of preparing the complexes. The present invention further relates to a radiopharmaceutical compositions comprising the complexes, to the use of the compositions for examining the renal function, and to a kit for preparing such compositions.

Abstract: In this method, one attaches one or more chelatant molecules to a mono- or polyamino intermediate compound which is temporarily immobilized on a solid phase by a splittable bond. Thereafter, said bond is split to release the desired conjugate moiety, whereby a reactive site is generated at the splitting site. The conjugate can be coupled to a protein homing factor using said reactive site; the latter being single per chelatant molecule, undesirable cross-linking during conjugation is substantially avoided.

Abstract: A lipolytic enzyme inhibitor is disclosed which comprises as an active ingredient at least one of a basic protein, a basic polypeptide and salt thereof. The inhibitor is useful as a dieting agent for the prevention of obesity and lipemia and as an additive for food and feed.

Abstract: The present invention relates to new stromelysin (human)-inhibitors, i.e., physiologically active substances BE-16627 represented by the general formula: ##STR1## wherein R represents a hydrogen atom or a methyl group, or pharmaceutically acceptable salts thereof, a process for the production and use thereof, and a microorganism producing the substance BE-16627.

Abstract: Disclosed is a process for producing alanylglutamine, which comprises reacting an N-(2-substituted)-propionylglutamine compound represented by the formula (I): ##STR1## where X represents halogen, alkylsulfonyloxy, or substituted or unsubstituted arylsulfonyloxy, with ammonia at a temperature of 60.degree. C. or below.In accordance with the present invention, highly purified alanylglutamine can be produced in a high yield, without racemization.

Abstract: The present invention provides a process for the production of calcium salts of hydantoic acids and which comprises the steps of reacting a hydantoin with a calcium base material such as calcium hydroxide in an aqueous medium at a sufficient temperature and for a sufficient period of time to form the calcium salt of the corresponding hydantoic acid and then separating the calcium salt of such acid from the reaction mass. This separation can include the further steps of cooling the reaction mass down to facilitate the precipitation of the acid/salt crystals and then separating the precipitate by means of filtering or centrifugating. These acids can then be subjected to a HNO.sub.2 -mediated decarbamoylation process followed by an optical resolution step to thus provide high yields of D-p-hydroxyphenylglycine which is a key synthetic immediate or building block for semi-synthetic penicillin and cephalosporins.

Abstract: The present invention is an improved process for the synthesis of asparagine, a non-essential amino acid useful in food and medical applications. The process utilizes mineral acid to make an intermediate beta-methyl aspartate from a reaction mixture of aspartic acid and methanol. The intermediate product is then amminated in situ and asparagine collected with no need for an isolation step of the intermediates.

Abstract: A process is described for the preparation of aqueous solutions of betaines of the formula ##STR1## in which: R.sup.1 is an alkyl radical having 6 to 22 carbon atoms or is a radical of the formula R'CONH(CH.sub.2).sub.z --, in which R' has the meaning of R.sup.1 and z is 2, 3 or 4, R.sup.2 is an alkyl radical having 1 to 4 carbon atoms or is a radical of the formula --(CH.sub.2).sub.m --OH, in which m is 1, 2 or 3, R.sup.3 is an alkyl radical having 1 to 4 carbon atoms or is a radical of said formula --(CH.sub.2).sub.m --OH and y is 1, 2 or 3. The aqueous betaine solutions are prepared by quaternization of the corresponding tertiary amines with an .omega.-halocarboxylic acid and with an alkali metal hydroxide in the aqueous phase. The quaternization is carried out continuously in two or three stirred tanks arranged in a cascade, defined process characteristics being maintained in each tank. Using the novel process, aqueous betaine solutions are obtained in high yield and purity in a simple manner.

Abstract: An N-(N'-long chain acyl-.beta.-alanyl)-.beta.-alanine represented by formula (1): ##STR1## wherein R represents a straight-chain or branched-chain alkyl or alkenyl group having from 7 to 23 carbon atoms; and M represents a hydrogen atom, an alkali metal, an ammonium, an alkylammonium, an alkanolammonium or a basic amino acid;or its salt and a detergent composition containing the same are disclosed.The detergent composition of the present invention is excellent in foaming power and gives a good feel after washing.

Abstract: This invention relates to novel diaminoalkanoic acid derivatives that inhibit platelet aggregation and thrombus formation in mammalian blood thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease and disseminated intravascular coagulation, to pharmaceutical compositions including such compounds, and to their use in inhibiting thrombus formation and platelet aggregation in mammals.

Abstract: Urethane oligomers having the formula:H.sub.2 C:CHCOORO[[COHNR'NHCO[O[CH.sub.2 ].sub.t CCH.sub.3 X].sub.m O].sub.n [CONHR'NHCOYR"Y].sub.p ].sub.q CONHR'NHCOOROCOCH:CH.sub.2(I)as well as process therefor are described. These oligomers are photocurable and useful as coatings and ink.

Abstract: Amino acids and amino acid derivatives bearing isotopic hydrogen labels at both the .alpha.- and .beta.-positions are produced when N-substituted azomethine derivatives of carboxylic acids and carboxylic acid derivatives are hydrogenated over metal catalysts in isotopically-enriched protic solvents with molecular hydrogen.

Abstract: A urethane derivative from amino acids has the formula ##STR1## wherein R represents --CH.sub.2 OH, --CHOH--CH.sub.3 or --(CH.sub.2).sub.3 --NH--CO--NHY, Y represents --H or --COOR', R' represents linear or branched alkyl, optionally unsaturated, having 8-24 carbon atoms, or a monocyclic cycloalkyl substituted by an alkyl whose total number of carbon atoms is equal to or greater than 10, or to the salts of the derivative of formula I or to a mixture of the derivatives of formula I and/or their salts. A method is given for the preparation of the urethane derivative of formula I, as are examples of cosmetic or pharmaceutical compositions containing the urethane derivative, as a hydrating agent, for the treatment of dry skin.

Abstract: Unsaturated phenone derivatives of the general formula I ##STR1##whereR.sup.1 is C.sub.1 -C.sub.4 -alkyl, cyclopropyl, cyclopentyl, cyclohexyl, indanonyl, tetralonyl, phenyl or phenyl in which some or all of the hydrogen atoms have been replaced by a C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy or C.sub.1 -C.sub.4 -thioalkyl group, or together with R.sup.2 or R.sup.6 forms an ethylene or propylene bridge,R.sup.2 to R.sup.6 are each hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy or C.sub.1 -C.sub.4 -thioalkyl, and R.sup.3, R.sup.4 and R.sup.5 may each additionally be hydroxyl, R.sup.2 or R.sup.6 may additionally together with R.sup.1 form an ethylene or propylene bridge and one or more, but not more than three, of the radicals R.sup.2 to R.sup.6 are a group of the general formula II ##STR2##whereK is C.sub.1 -C.sub.10 -alkylene which may contain 1 or 2 oxygen or sulfur atoms,Y is straight-chain or branched C.sub.1 -C.sub.10 -alkylene or is C.sub.1 -C.sub.

Abstract: A photographic processing composition containing at one compoud represented by formula (I) ##STR1## wherein R.sub.1 represents a hydrogen atom, an aliphatic group, or an aromatic group, L.sub.1 and L.sub.2 each represents a divalent bonding group including an alkylene group and/or an arylene group; X represents a ##STR2## group (wherein R.sub.a, R.sub.b and R.sub.c each represents a hydrogen atom, an aliphatic group or an aromatic group, and R.sub.d represents an aliphatic group or an aromatic group); and Y represents a carboxy group, a hydroxy group, a phosphono group, a sulfo group or a salt thereof. The processing composition does not produce precipitate or sludge even when contaminated by metallic ions. A processing method using the processing composition is also disclosed.

Abstract: A process for producing an amide or an ester represented by the general formula W-A-B-Y which involves reacting an ester sulfonium salt represented by the general formula: ##STR1## with a nucleophilic agent represented by the general formulaH--B--Ywherein B represents a nucleophilic group, and wherein the members of the formula are further described in detail in the specification.

Abstract: Lipophilic amphoteric surface active compositions exhibiting remarkable W/O emulsifying property and good stabililty against oxidation, comprising betaines having the general formula ##STR1## wherein R.sub.1 --CO is an acyl radical of estolides, R.sub.2 is an alkylene group having 1 to 3 carbon atoms and n is an integer from 1 to 3.

Abstract: A compound of the formula:AN/xSwherein A represents an amino acid, N represents an .alpha.-keto acid, S represents a lower alcohol or acetone; and x ranges from 0.1 to 3.

Abstract: This invention pertains to amino acids attached to a solid support in a racemization free manner and to a method of covalently linking amino acids to solid supports for use in solid phase peptide syntheses.

Abstract: Site-specific heterobifunctional crosslinkers of the formula:X--COCH(NH.sub.2)--Y--Zwhere X is a carbonyl reactive group, Y is a variable length spacer, and Z is a thiol reactive group, are useful for the specific labelling of biomolecules or bioaffecting molecules.

Abstract: Novel chemical compounds are provided which selectively inhibit the metabolism of dipeptidase (E.C.3.4.13.11) and therefore are useful in combination with antibacterial products. These chemical compounds are z-2-acylamino-3-monosubstituted propenoates.